Hextar Healthcare (7803) Fundamentals 2026 — Revenue Analysis | SniperIQ
Hextar Healthcare (7803) is a MY-listed Basic Materials company in Chemicals - Specialty with a market capitalization of RM66M, trading at RM0.06 on the KLS. This SniperIQ fundamentals page covers Hextar Healthcare's valuation, profitability (net margin -31.4%), revenue (RM148M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hextar Healthcare's market cap?
Hextar Healthcare (7803) has a market capitalization of approximately RM66M, trading at RM0.06 on the KLS. Market cap moves with the live share price.
What is Hextar Healthcare's P/E ratio?
Hextar Healthcare's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.1x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Hextar Healthcare?
Hextar Healthcare runs a net profit margin of -31.4%, a gross margin of -4.8%, and an operating margin of -22.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hextar Healthcare generate?
Hextar Healthcare reported revenue of RM148M for fiscal year 2025, with net income of -RM45M and earnings per share (EPS) of -0.0408. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hextar Healthcare pay a dividend?
Hextar Healthcare does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Hextar Healthcare financially healthy?
Hextar Healthcare carries a debt-to-equity ratio of 0.01x and a current ratio of 5.79x, with a market beta of -0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hextar Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hextar Healthcare (7803) the key facts are: market cap RM66M, revenue RM148M, 52-week range 0.05-0.12. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Hextar Healthcare's full fundamentals live
Get Hextar Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.